Industry
Biotechnology
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Loading...
Open
63.76
Mkt cap
1.9B
Volume
29K
High
63.76
P/E Ratio
-57.72
52-wk high
86.53
Low
61.50
Div yield
N/A
52-wk low
31.00
Portfolio Pulse from
November 13, 2024 | 1:45 am
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 10:47 am
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 12:12 pm
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 7:20 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 6:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 2:45 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
June 20, 2024 | 5:28 pm
Portfolio Pulse from Benzinga Newsdesk
June 13, 2024 | 10:28 am
Portfolio Pulse from Benzinga Newsdesk
June 12, 2024 | 7:26 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.